Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.

摘要: The object of this study was to differentiate losartan, an AT1-selective angiotensin II (ANG II) receptor antagonist, from enalapril, angiotensin-converting enzyme (ACE) inhibitor, by measuring forearm vascular responses AI, AII, and bradykinin. Eight healthy men were studied in a randomised, 4-period crossover which placebo, enalapril (10 mg), losartan (20 mg) (100 given double-blind on separate occasions. Forearm blood flow measured venous occlusion plethysmography during sequential infusions ANG I, II, bradykinin into the brachial artery 4-6 h after dosing. Analysis variance for repeated measures indicated that inhibited constriction I (both p < 0.02) dose-dependent manner without significantly influencing vasodilator Enalapril AI similarly 100 mg augmented (p 0.0001). In human vasculature, oral (20-100 inhibits vasoconstriction bradykinin-induced vasodilation, whereas selectively I-induced while potentiating effect